All In Biotech

Drug Trial Radar · NCT01846611

A Study Comparing the Combination of Trabectedin (YONDELIS) and DOXIL/CAELYX With DOXIL/CAELYX for the Treatment of Advanced-Relapsed Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer

A Randomized, Open-Label Study Comparing the Combination of YONDELIS and DOXIL/CAELYX With DOXIL/CAELYX Monotherapy for the Treatment of Advanced-Relapsed Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer

Last checked: Nov 19, 2026Latest source record: Apr 1, 2019 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 581 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

581

Actual

Start

Oct 16, 2013

Primary completion

Jan 18, 2018

Study completion Nov 16, 2018

Sponsor

Lead sponsor
Janssen Research & Development, LLCJohnson & Johnson (Janssen) (JNJ)
Sponsor type
Industry
Collaborators
PharmaMar
First posted
May 3, 2013

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
Who can join
Female only, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to assess the efficacy and safety of trabectedin+DOXIL as a third-line chemotherapy regimen (treatment) in patients with platinum-sensitive advanced-relapsed epithelial ovarian, primary peritoneal, or fallopian tube cancer who received 2 previous lines of platinum-based chemotherapy.

Conditions

  • Ovarian Neoplasms
  • Peritoneal Neoplasms
  • Fallopian Tube Neoplasms

Interventions

  • TrabectedinDrug

    1.1 mg/m\^2 administered intravenously over approximately 3 hours on Day 1 of each 21-day treatment cycle.

  • DOXILDrug

    30 mg/m\^2 administered intravenously over approximately 90 minutes on Day 1 of each 21-day treatment cycle.

  • DexamethasoneDrug

    20 mg administered intravenously on Day 1 of each 21-day treatment cycle approximately 30 minutes prior to study drug infusion.

  • DOXILDrug

    50 mg/m\^2 administered intravenously over approximately 90 minutes on Day 1 of each 28-day treatment cycle.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Overall Survival (OS)Time frame: Up to 4.3 years

Locations

138 sites in 10 countries. Site status is shown where the registry gives one.

  • Site not named

    Birmingham, Alabama

  • Site not named

    Phoenix, Arizona

  • Site not named

    Scottsdale, Arizona

  • Site not named

    Sedona, Arizona

  • Site not named

    Tucson, Arizona

  • Site not named

    Hot Springs, Arkansas

  • Site not named

    Greenbrae, California

  • Site not named

    La Jolla, California

  • Site not named

    Los Angeles, California

  • Site not named

    Orange, California

  • Site not named

    Sacramento, California

  • Site not named

    Englewood, Colorado

  • Site not named

    New Britain, Connecticut

  • Site not named

    New Haven, Connecticut

  • Site not named

    Stamford, Connecticut

  • Site not named

    Fort Myers, Florida

  • Site not named

    Jacksonville, Florida

  • Site not named

    Miami, Florida

  • Site not named

    Sarasota, Florida

  • Site not named

    St. Petersburg, Florida

  • Site not named

    Tampa, Florida

  • Site not named

    Atlanta, Georgia

  • Site not named

    Savannah, Georgia

  • Site not named

    Chicago, Illinois

  • Site not named

    Park Ridge, Illinois

  • Site not named

    Indianapolis, Indiana

  • Site not named

    Louisville, Kentucky

  • Site not named

    Covington, Louisiana

  • Site not named

    New Orleans, Louisiana

  • Site not named

    Scarborough, Maine

  • Site not named

    Worcester, Massachusetts

  • Site not named

    Detroit, Michigan

  • Site not named

    Lansing, Michigan

  • Site not named

    Duluth, Minnesota

  • Site not named

    Edina, Minnesota

  • Site not named

    Columbia, Missouri

  • Site not named

    Kansas City, Missouri

  • Site not named

    Hackensack, New Jersey

  • Site not named

    Morristown, New Jersey

  • Site not named

    New Brunswick, New Jersey

Showing 40 of 138 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.